Initial Therapy of Advanced Anaplastic Thyroid Cancer via Targeting VEGFR-2: A Case Report

Preclinical studies have demonstrated that Apatinib, major targeting vascular endothelial growth factor receptor-2 (VEGFR-2), could inhibit the proliferation of anaplastic thyroid carcinoma (ATC) cells in vitro and in vivo. The efficacy and safety in ATC patients, however, remains unknown. Here, we...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Lin, Jiao, Qiong, Jin, Yuchen, Fu, Hao, Zhang, Huizhen, Chen, Libo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6896907/
https://www.ncbi.nlm.nih.gov/pubmed/31819530
http://dx.doi.org/10.2147/OTT.S223727

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6896907/
https://www.ncbi.nlm.nih.gov/pubmed/31819530
http://dx.doi.org/10.2147/OTT.S223727

Ejemplares similares